Revelation Biosciences, Inc. announced that Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells (PBMCs). This effect was observed when PBMCs were exposed to clinically relevant promoter molecules of inflammation, including high mobility box protein-1 (HMGB-1) and lipopolysaccharide (LPS) in vitro. HMGB-1 is associated with tissue injury, while LPS is linked to bacterial infection.
The study demonstrated that priming with Gemini significantly decreased proinflammatory cytokines and significantly increased anti-inflammatory cytokines, relative to placebo. This fundamental change in cellular responsiveness supports the hypothesis that Gemini can protect against inflammation-mediated damage. The observed response is considered an excellent surrogate for Gemini's potential in target indications.
Revelation anticipates demonstrating this same protective effect in cells collected from patients treated with Gemini in its ongoing Phase 1b clinical study for Chronic Kidney Disease (CKD). Top-line data from the PRIME clinical study, which will include this cellular-level demonstration of protection, are expected by mid-2025. These results further validate Gemini's mechanism of action and its potential for the GEM-CKD, GEM-AKI, and GEM-PSI programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.